Filing Flows

Filing Flows › Axsome Therapeutics (AXSM) › Next earnings date

Axsome Therapeutics (AXSM) earnings: beat the estimate

Axsome Therapeutics (AXSM) reported on Nov 2, 2026 and beat the EPS estimate: −$0.25 against −$0.64 (+60.9%). Revenue was $260M for Q3 2026, +52% year over year. It beat the EPS estimate in 40% of the quarters on record.

Last result+60.9% vs estimate
Beat rate40%

The last report

Axsome Therapeutics reported revenue of $260M for the third quarter 2026 (+52% Y/Y), net loss $12.9M: Product $250M, Royalty and Milestone Revenue $9.7M. How it makes money → · Every quarter →

Axsome Therapeutics: EPS against the estimate, last 5 reportsAxsome Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.90−$0.94Nov 25−$0.73−$0.56Feb 26−$0.86−$1.26May 26−$0.78−$0.99Aug 26−$0.64−$0.25Nov 26
Latest (Nov 26): Estimate −$0.64, Reported −$0.25.
AXSM: the stock's move on each reportAXSM: the stock's move on each reportAug 10, 2026+1.4%May 4, 2026+8.0%Feb 23, 2026-7.5%Nov 3, 20250.0%

Axsome Therapeutics' latest quarter

Axsome Therapeutics, Q3 2026: revenue $260M (+52% year over year), operating margin -4.3%, net loss $12.9M, operating cash flow −$9.5M. The chart follows the revenue to costs, profit and cash.

Questions

Did Axsome Therapeutics beat earnings?

Axsome Therapeutics (AXSM) reported on Nov 2, 2026 and beat the EPS estimate: −$0.25 against −$0.64 (+60.9%).

When does AXSM report earnings?

The next date is not set yet.

Does Axsome Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.